Analytical Data
-
基因名
KGF/FGF-7
- Application
-
生物活性
The ED50 is ≤10 ng/mL as measured by 4MBr-5 cells, corresponding to a specific activity of ≥1 × 105 units/mg. Measured in a cell proliferation assay using 4MBr 5 rhesus monkey epithelial cells. The ED50 for this effect is 8.477 ng/mL, corresponding to a specific activity is 1.18×105 units/mg.
-
别名
rMuFGF-7; HBGF-7; KGF
-
种属
Mouse
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
P36363
-
表达区间
C32-T194
-
蛋白长度
Full Length of Mature Protein
-
分子量
19 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KGF (keratinocyte growth factor) and FGF-7 (fibroblast growth factor 7) are key members of the FGF family, playing crucial roles in wound healing, hair growth, and epithelial cell proliferation. They primarily function by promoting the survival and proliferation of keratinocytes, which are essential for skin regeneration and repair. Understanding their mechanisms can lead to advancements in regenerative medicine and therapies for skin conditions. Previous studies have highlighted their potential in treating disorders characterized by impaired epithelial repair and have shown promising results in preclinical models. The recombinant production of KGF/FGF-7 allows for the exploration of their therapeutic applications in a more controlled and efficient manner, facilitating investigations into their dosage, efficacy, and safety profiles. Furthermore, the development of these recombinant proteins has implications for clinical settings, including dermatology and plastic surgery, where enhancing wound healing and tissue regeneration is critical. Ongoing research aims to optimize their formulation and delivery methods to maximize their bioactivity and therapeutic outcomes, thereby paving the way for innovative treatments for a variety of skin-related ailments and procedures.
